MRK, Daiichi Begin Pivotal Esophageal Cancer Study With ADC Drug

Merck (MRK) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), in certain patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).The IDeate-Esophageal01 study will evaluate the safety and efficacy of I-DXd versus an investigator’s choice of chemotherapy in ESCC patients whose disease progressed following treatment with a platin ...